

Trend Macrolytics, LLC Donald Luskin, Chief Investment Officer Thomas Demas, Managing Director Michael Warren, Energy Strategist

#### Data Insights: Covid-2019 Monitor

Tuesday, April 27, 2021

## The global scorecard



#### For more information contact us:

Donald Luskin: 312 273 6766 don@trendmacro.com

Thomas Demas: 704 552 3625 tdemas@trendmacro.com

Copyright 2021 Trend Macrolytics LLC. All rights reserved. This document is not to be forwarded to individuals or organizations not authorized by Trend Macrolytics LLC to receive it. For information purposes only; not to be deemed to be recommendations for buying or selling specific securities or to constitute personalized investment advice. Derived from sources deemed to be reliable, but no warranty is made as to accuracy.

## The US scorecard



Source: Johns Hopkins, Dept. of Health and Human Services, CDC, TrendMacro calculations

| nonny   | outin            |                  |                                   |                 |                                  |              | iu               |          |                              |                |        |         |
|---|------------------|------------------|-----------------------------------|-----------------|----------------------------------|--------------|------------------|----------|------------------------------|----------------|--------|---------|
| US overall  |                  |                  |                                   |                 | Uver last day                    |              |                  |          |                              | Immunity       | Full   | Partial |
| 302.27 million doses distributed                    |                  |                  |                                   |                 |                                  |              | +0.00 milli      | on/day   |                              | 05             | 28.7%  | 42.2%   |
| 238.82 million persons partially immunized          |                  |                  |                                   |                 |                                  |              | +2.13 [1]]       | on/day   | 1&1                          | UK             | 19.0%  | 49.7%   |
| 145. To million persons fully immunized             |                  |                  |                                   |                 |                                  |              | +1.00 [[]]       | on/day   | 3%                           | France         | 8.1%   | 20.7%   |
| 33.19 million obsta long term care residents (staff |                  |                  |                                   |                 |                                  |              | +1.13 [[]]       | lion/day |                              | Spain          | 8.4%   | 23.1%   |
| 7.79 millioi  | /stall           |                  |                                   | +0.000 mii      |                                  | . DC         | Germany          | 7.2%     | 23.7%                        |                |        |         |
| /9.0% of c  |                  | doses adm        | inistered                         | 00 70/ 6 11     | •                                |              |                  | Moderna  | Pfizer                       | Italy          | 8.8%   | 21.2%   |
| 43.4% of US pop partial                             |                  |                  |                                   | 29.7% TUI       | immunity                         |              |                  | 44%      | 5570                         | Australia      | 1.2%   | 0.6%    |
| TUU% OF LTC partial                                 |                  |                  |                                   | 64.1% full      | immunity                         |              |                  |          |                              | Israel         | 58.6%  | 62.3%   |
|   |                  |                  |                                   |                 |                                  | At today's   | s dosing p       | ace,     |                              | Canada         | 2.1%   | 29.9%   |
|   |                  |                  | 7                                 |                 | every American >18 immune in     |              |                  |          | Japan                        | 0.7%           | 1.6%   |         |
| State   |                  |                  |                                   |                 | 12() davs                        |              |                  |          | Africa                       | 0.4%           | 0.9%   |         |
| Immunition distributed                              |                  |                  | 4                                 |                 |                                  |              |                  |          | India                        | 1.6%           | 8.1%   |         |
|   |                  |                  |                                   | by Aug 24, 2021 |                                  |              |                  |          | Brazii<br>Global data differ | 0.0%           | 12.9%  |         |
|   |                  |                  | 47.2% of population >18 immunized |                 |                                  |              |                  | nizea    | China NA                     |                |        |         |
| AK Partial Immunity                                 |                  |                  | Be                                | st              | 13.5% previously tested positive |              |                  |          |                              |                |        |         |
| 55.4% as % population                               |                  |                  | 60.7% VS 60% adult herd imm       |                 |                                  |              | imunity          |          | 50.1%                        |                |        |         |
| 41.1%   |                  |                  | mulation                          | Mid             | dle                              |              |                  |          |                              |                | 5Z.1%  |         |
| 34.0%   |                  | as % µu          | ιραιατιοπ                         | J               |                                  | 14/1         | 1                |          |                              | VT             | 30.3%  |         |
|   |                  |                  |                                   | Wo              | rst                              |              | 10/              |          |                              | VI             |        |         |
|   |                  |                  |                                   |                 |                                  | 43.4%        |                  |          |                              | 54.0%          | 48.2%  |         |
|   |                  |                  |                                   |                 |                                  | 44.8%        | 4.0 %            |          |                              | 5Z.7%          | 59.5%  |         |
|   | \\\\             |                  | МТ                                | ND              | MAN                              | 33.5%        | MI               |          | NV                           | 35.6%          | 29.5%  |         |
|   | VVA              | IU<br>41.10/     | IVI I<br>47.00/                   | ND<br>42.20/    |                                  | IL<br>47.00/ |                  |          |                              | IVIA<br>E1.00/ |        |         |
|   | 40.4 %           | 41.170<br>22.40/ | 47.9%                             | 43.2 %          | 45.5%                            | 47.3%        | 40.470           |          | 47.7%                        | 52.60/         |        |         |
|   | 44.0 %<br>20 60/ | 33.4 <i>%</i>    | 40.0 %                            | 30.0 %          | 40.0%                            | 40.1%        | 41.070<br>20.00/ |          | 40.9%                        | 24.00/         |        |         |
|   | 0R               | 20.0 /0          | 30.3 /0                           | 52.0 /0<br>SD   | <u>32.0 /0</u>                   | 20.9 /0      | 0H               | PΔ       | 32.2 /0<br>N I               | 04.0 /0<br>CT  | RI     | 1       |
|   | 1/ 0%            | /1.3%            | /3.8%                             | 51.6%           | 11.8%                            | /11.3%       | /5.3%            | 19.5%    | 17 3%                        | 55.2%          | 52.8%  |         |
|   | 12.6%            | 38.7%            | 33.6%                             | 11.0%           | /12.3%                           | 25.1%        | 30.6%            | 43.3%    | /0 0%                        | 53.2%          | 50.7%  |         |
|   | 28.8%            | 26.6%            | 26.9%                             | 3/1 9%          | 32.0%                            | 25.3%        | 30.5%            | 30.2%    | 33.0%                        | 36.4%          | 34.7%  |         |
|   | CA               | 20.070<br>UT     | <u>20.070</u>                     | 04.070<br>NF    | M0                               | KY           | WV               | VA       | MD                           | DF             | 07.770 |         |
|   | 48.5%            | 39.1%            | 45.7%                             | 46.2%           | 43.8%                            | 44.4%        | 48.0%            | 46.5%    | 48.4%                        | 49.0%          |        |         |
|   | 47.2%            | 38.0%            | 45.2%                             | 42.6%           | 36.9%                            | 40.4%        | 35.3%            | 45.6%    | 46.6%                        | 45.4%          |        |         |
|   | 28.8%            | 22.0%            | 30.3%                             | 31.2%           | 26.1%                            | 30.6%        | 29.0%            | 30.8%    | 31.9%                        | 30.2%          |        |         |
|   | 20.070           | AZ               | NM                                | KS              | AR                               | TN           | NC               | SC       | DC                           | 00.270         |        |         |
|   |                  | 45.7%            | 50.6%                             | 46.7%           | 45.5%                            | 41.9%        | 46.7%            | 44 4%    | 58 5%                        |                |        |         |
|   |                  | 39.9%            | 50.1%                             | 41.9%           | 34.9%                            | 33.6%        | 38.5%            | 35.7%    | 45.9%                        |                |        |         |
|   |                  | 27.6%            | 35.7%                             | 30.1%           | 24.2%                            | 23.2%        | 27.5%            | 25.7%    | 27.9%                        |                |        |         |
|   |                  |                  |                                   | OK              | LA                               | MS           | AL               | GA       |                              | 4              |        |         |
|   |                  |                  |                                   | 49.2%           | 41.3%                            | 42.5%        | 42.9%            | 43.8%    |                              |                |        |         |
|   |                  |                  |                                   | 38.1%           | 31.9%                            | 30.2%        | 31.6%            | 34.1%    |                              |                |        |         |
|   |                  |                  |                                   | 28.7%           | 25.9%                            | 22.3%        | 21.8%            | 22.5%    |                              |                |        |         |
| HI  |                  |                  |                                   | TX              |                                  |              |                  |          | FL                           | ] [            | PR     |         |
| 50.9%   |                  |                  |                                   | 43.6%           |                                  |              |                  |          | 48.7%                        |                | 49.4%  |         |
| 50.3%   |                  |                  |                                   | 37.2%           |                                  |              |                  |          | 40.5%                        |                | 35.3%  |         |
| 33.8%   |                  |                  |                                   | 25.3%           | As of Apr 26                     |              |                  |          | 27.5%                        |                | 22.7%  |         |

Rolling out the vaccines in the US and the world

\*\* One dose of Pfizer/Moderna counts as half an immunity, one dose of J&J as a full immunity Source: <u>CDC</u>, <u>CDC</u>, <u>Our World in Data</u>, TrendMacro calculations



Source: Johns Hopkins, Covid Act Now, TrendMacro calculations



Source: Distributions <u>CDC</u>, Comorbidities <u>CDC</u>, TrendMacro calculations

## Recommended reading

#### Time to End Outdoor Mask Edicts

Scott Gottlieb *Wall Street Journal* April 25, 2021

### Simple Sabotage Field Manual

Strategic Services Unit United States War Department January 17, 1944 Nottingham doctor seeing 'deluge' of aggressive cancer symptoms in patients after year of lockdowns Ben Reid Nottinghamshire Live April 26, 2021

### AZ parent slams school board for 'double standard' of hosting retirement party, canceling prom

Talia Kaplan Fox News April 25, 2021

### <u>Thousands march in London against lockdowns,</u> <u>COVID vaccine passports</u>

Melissa Klein *New York Post* April 24, 2021

#### <u>The Failure of Imperial College Modeling Is Far</u> Worse than We Knew

Phillip W. Magness *American Institute for Economic Research* April 22, 2021

## Meme of the day



Source: Our beloved clients, and Power Line blog "The Week in Pictures"



The coronavirus <u>case</u> accelerometer... tracking the world's infection curves *Share of infected population from first day with 100 confirmed cases, log scale* 

Source: Johns Hopkins, TrendMacro calculations



The coronavirus <u>mortality</u> accelerometer ... tracking the world's fatality curves *Share of deceased population from day of first fatality* 



Source: Johns Hopkins, TrendMacro calculations

Requirement to <u>Open Up America Again</u>: 14-day "downward trajectory" in new cases *14-day moving average, last 14 days Most recent value displayed* • High • Low Downward trajectory Five best Upward trajectory Five worst



Source: Johns Hopkins, TrendMacro calculations

Alt requirement to <u>Open Up America Again</u>: 14-day "downward trajectory" in pos tests *14-day moving average, last 14 days Most recent value displayed* • High • Low Downward trajectory Five best Upward trajectory Five worst



Source: Covid Act Now, TrendMacro calculations



Source: Johns Hopkins, TrendMacro calculations



Source: Johns Hopkins, TrendMacro calculations

#### Patient zero... and then everyone else 5,000 6.0% China As of Apr 26 4,500 0.73 bp of population infected 5.0% 4,000 0.03 bp of population mortalities ia. 37.4 median population age 3,500 Daily new cases and deaths 4.0% Cume fatality rate 4.73% 3,000 2-week fatality rate 0.48% 2,500 3.0% rate 2,000 102,399 cases cumulative +15 cases today 2.0% 1,500 4,845 deaths cumulative -day moving average case 1,000 1.0% +0 deaths today 500 0.0%





Source: Johns Hopkins, TrendMacro calculations

## Impact in the largest economies



Source: Johns Hopkins, TrendMacro calculations



Source: Johns Hopkins, TrendMacro calculations





## Impact in other hot-spots



#### Impact in the BRICs ex-China 400,000 4.0% India As of Apr 26 350,000 3.5% 131.55 bp of population infected 17,636,186 cases cumulative \_2300,000 3.0% 1.48 bp of population fatalities +323,023 cases today 26.8 median population age 2.5% 2-week fatality rate 1.68% xx200,000 2.0% Cume fatality rate 1.12% ≧150,000 1.5% 7-day moving average cases 100,000 197,894 deaths cumulative 1.0% +2,771 deaths today 50,000 0.5% 0.0% Dec 31 Jan 28 Feb 25 Mar 24 Apr 21 May 19 Jun 16 Jul 14 Aug 11 Sep 8 Oct 6 Dec 1 Dec 29 Jan 26 Feb 23 Mar 23 Apr 20 Nov 3 35,000 5.0% 2-week fatality rate 4.38% Russia 4.5% 30,000 32.65 bp of population infected 4.0% Cume fatality rate 2.26% 25,000 gaily new cases and deaths 20,000 15,000 10,000 0.74 bp of population fatalities 3.5% 39.6 median population age 3.0% 2.5% 2.0% rat 4,717,321 cases cumulative +8,681 cases today 1.5% 106,783 deaths cumulative 1.0% +349 deaths today 5,000 0.5% 0.0% Dec 31 Jan 28 Feb 25 Mar 24 Apr 21 May 19 Jun 16 Jul 14 Aug 11 Sep 8 Oct 6 Nov 3 Dec 1 Dec 29 Jan 26 Feb 23 Mar 23 Apr 20 120,000 8% Brazil 7% 2-week fatality rate 3.95% 100,000 685.89 bp of population infected 6% 18.71 bp of population fatalities Daily new cases and deaths Cume fatality rate 2.73% 80,000 33.5 median population age 14,369,423 cases cumulative +28,636 cases today 60,000 3% <sup>(</sup> 40,000 20,000 1% 391,936 deaths cumulative +1,139 deaths today mon 0% Dec 31 Jan 28 Feb 25 Mar 24 Apr 21 May 19 Jun 16 Jul 14 Aug 11 Sep 8 Oct 6 Nov 3 Dec 1 Dec 29 Jan 26 Feb 23 Mar 23 Apr 20

Source: Johns Hopkins, TrendMacro calculations



# Impact in Africa, continued



Source: Johns Hopkins, TrendMacro calculations